These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10689153)

  • 1. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection.
    Briles DE; Hollingshead S; Brooks-Walter A; Nabors GS; Ferguson L; Schilling M; Gravenstein S; Braun P; King J; Swift A
    Vaccine; 2000 Feb; 18(16):1707-11. PubMed ID: 10689153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
    Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS
    J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
    Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.
    Briles DE; Ades E; Paton JC; Sampson JS; Carlone GM; Huebner RC; Virolainen A; Swiatlo E; Hollingshead SK
    Infect Immun; 2000 Feb; 68(2):796-800. PubMed ID: 10639448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
    Daniels CC; Coan P; King J; Hale J; Benton KA; Briles DE; Hollingshead SK
    Infect Immun; 2010 May; 78(5):2163-72. PubMed ID: 20194601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
    McDaniel LS; Sheffield JS; Delucchi P; Briles DE
    Infect Immun; 1991 Jan; 59(1):222-8. PubMed ID: 1987036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
    Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
    Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
    Briles DE; Hollingshead SK; Nabors GS; Paton JC; Brooks-Walter A
    Vaccine; 2000 Dec; 19 Suppl 1():S87-95. PubMed ID: 11163470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and mucosal protective immunity to pneumococcal surface protein A.
    Briles DE; Tart RC; Wu HY; Ralph BA; Russell MW; McDaniel LS
    Ann N Y Acad Sci; 1996 Oct; 797():118-26. PubMed ID: 8993356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.
    Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y
    Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae.
    Roche H; Ren B; McDaniel LS; Håkansson A; Briles DE
    Infect Immun; 2003 Aug; 71(8):4498-505. PubMed ID: 12874329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.